# High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease

Verena Zuber[1,2], Dipender Gill[1], Mika Ala-Korpela[3,4], Claudia Langenberg[5], Adam Butterworth[6,7,8,9,10,11], Leonardo Bottolo[12,13,2], and Stephen Burgess[2,6]

[1]Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
[2]MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK
[3]Computational Medicine, Faculty of Medicine, University of Oulu & Biocenter Oulu, Oulu, Finland
[4]NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland
[5]MRC Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK
[6]British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
[7]British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
[8]National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, UK
[9]National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK
[10]Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
[11]Department of Human Genetics, Wellcome Sanger Institute, Hinxton, UK
[12]Department of Medical Genetics, School of Clinical Medicine, University of Cambridge, Cambridge, UK
[13]The Alan Turing Institute, London, UK

June 6, 2020

**Background**: Genetic variants can be used to prioritize risk factors as potential therapeutic targets via Mendelian randomization (MR). An agnostic statistical framework using Bayesian model averaging (MR-BMA) can disentangle the causal role of correlated risk factors with shared genetic predictors. Here, our objective is to identify lipoprotein measures as mediators between lipid-associated genetic variants and coronary artery disease (CAD) for the purpose of detecting therapeutic targets for CAD.

**Methods**: As risk factors we consider 30 lipoprotein measures and metabolites derived from a high-throughput metabolomics study including 24,925 participants. We fit multivariable MR models of genetic associations with CAD estimated in 453,595 participants (including 113,937 cases) regressed on genetic associations with the risk factors. MR-BMA assigns to each combination of risk factors a model score quantifying how well the genetic associations with CAD are explained. Risk factors are ranked by their marginal score and selected using false discovery rate (FDR) criteria. We perform supplementary and sensitivity analyses varying the dataset for genetic associations with CAD.

**Results**: In the main analysis, the top combination of risk factors ranked by the model score contains apolipoprotein B (ApoB) only. ApoB is also the highest ranked risk factor with respect to the marginal score (FDR$<$ 0.005). Additionally, ApoB is selected in all sensitivity analyses. No other measure of cholesterol or triglyceride is consistently selected otherwise.

**Conclusions**: Our agnostic genetic investigation prioritizes ApoB across all datasets considered, suggesting that ApoB, representing the total number of hepatic-derived lipoprotein particles, is the primary lipid determinant of CAD.

Wordcount: 249/250

---

# Key messages

- It is a common consensus that lipoproteins increase cardiovascular disease risk, yet little is known about the exact mechanisms.
- We use genetic associations with high-throughput metabolomics features to draw a detailed picture of lipid traits and characteristics allowing for an unprecedented resolution when considering lipids as risk factors for cardiovascular disease.
- This study integrates genetic data from a large scale metabolomics study including 25,000 samples and the largest study on cardiovascular disease risk including 113,937 cases and 339,658 controls.
- MR-BMA, a novel algorithm for multivariable MR is used to identify the most likely causal lipid determinants of cardiovascular disease from a large set of candidate risk

factors with shared genetic predictors.

- Our agnostic genetic investigation prioritizes apolipoprotein B across all datasets considered, suggesting that apolipoprotein B, representing the total number of hepatic-derived lipoprotein particles, is the primary lipid determinant of cardiovascular disease risk.

# Introduction

Genetic variants have the potential to contribute greatly to our understanding of mechanisms underlying disease processes, and to guide target validation for pharmacological and clinical interventions that reduce disease risk [1]. Coronary artery disease (CAD) is the most common cause of death globally. While it has been shown that genetic variants predisposing individuals to higher levels of low-density lipoproteins (LDL)-cholesterol also associate with increased CAD risk [2], genetic variants predisposing individuals to higher levels of high-density lipoproteins (HDL)-cholesterol are not associated with CAD risk [3] after accounting for other lipid traits. These genetic analyses may suggest that LDL-cholesterol is a causal risk factor for CAD risk, but HDL-cholesterol is not − as has generally been observed in clinical trials of lipid-altering therapies [4, 5, 6]. Genetic studies have also suggested that triglyceride levels are an independent risk factor for CAD risk [7]. Triglycerides are another component of body fat which are transported by lipoprotein particles, and in particular by very low density lipoproteins (VLDL). However, two recent studies showed that genetic associations with CAD risk are proportional to the change in apolipoprotein B (ApoB), the primary protein component of VLDL, LDL, and intermediate-density lipoprotein (IDL) particles, and that LDL-cholesterol and triglycerides do not appear to be independent risk factors for CAD after accounting for ApoB [8, 9].

Genome-wide association studies (GWAS) are increasingly used to combine genomic profiling with high-throughput molecular measures on a large scale, including tens of thousands of samples, to explore the genetic regulation of molecular processes. For example, Kettunen et al. have combined high-throughput metabolomics with genomic profiling on nearly 25 000 individuals [10]. Given the large sample size, these studies are well powered to explore the causal role of molecular mechanisms. The metabolomics study by Kettunen et al. was conducted using nuclear magnetic resonance (NMR) spectroscopy to provide a detailed characterization of lipid-related traits, including 14 size categories of lipoprotein particles ranging from small HDL to extra-extra-large VLDL. For each lipoprotein category, measurements are available of cholesterol, triglycerides, cholesterol ester, and phospholipid content. Additional mean diameter of the lipoprotein particles is measured for some lipoprotein size categories. Measurements also include apolipoprotein A1 and ApoB, sphingomyelins, fatty acids, and phosphoglycerides (Supplementary Table A2).

Previous MR studies on lipid determinants for CAD risk have included only a few curated lipid traits at a time [8, 9]. In this study, we build on a high-throughput metabolomics data resource [10] to investigate a much wider set of lipoprotein measurements as candidate risk factors for CAD. We use a recently published algorithm called Mendelian randomization with Bayesian model averaging (MR-BMA) [11] that applies principles from high-dimensional data

analysis and machine learning to detect causal risk factors from a large set of candidate risk factors. Our goal is to select the lipoprotein measures that are the most likely causal risk factors for CAD.

# Methods

## Variable selection method for finding likely causal risk factors

We provide a brief outline of the MR-BMA method here. More details are given in the Supplementary Material, and a diagram illustrating the method is shown in Figure 1.

We consider each set of risk factors in turn: all single risk factors, all pairs of risk factors, all triples, and so on. For each set of risk factors, we undertake a multivariable MR analysis using weighted regression based on summarized genetic data. We assess goodness-of-fit in the regression model, and assign a score to the risk factor set that is the model posterior probability of that set being the true causal risk factors. We repeat this to get a posterior probability for all models (i.e. all sets of risk factors). Then, for each of the candidate risk factors, we sum up the posterior probability over models including that risk factor to compute the marginal inclusion probability for the risk factor, representing the probability of that risk factor being a causal determinant of disease risk. We also calculate the model-averaged causal effect, representing the average causal effect across models including that risk factor. P-values are calculated for each risk factor using a permutation method, with adjustment for multiple testing via the Benjamini and Hochberg false discovery rate (FDR) procedure [12].

## Study design

A summary of our study design is given in Figure 2. The three key steps in designing a two-sample multivariable MR study are instrument selection, risk factor selection, and the choice of outcome data, including main and sensitivity analysis.

## Selecting lipid-associated variants as instrumental variables

We took an initial list of 185 variants associated with blood lipids (LDL-cholesterol, HDL-cholesterol or triglycerides) in the Global Lipid Genetics Consortium at a genome-wide level of significance ($p < 5 \times 10^{-8}$) [7] which was pruned at a linkage disequilibrium threshold of $r^2 < 0.05$, and further refined by genomic distance, excluding variants that are less than 1 megabase pair apart, to provide a list of $n = 150$ genetic variants. We selected these lipid-associated genetic variants as instrumental variables because we wanted to investigate lipid determinants of CAD risk. This is important to keep in mind when interpreting the results as the prioritization of risk factors by MR-BMA is conditional on the genetic variants selected as instrumental variables. There are two direct consequences of this choice. Firstly, this choice of instrumental variables will downweight non-lipid risk factors, and so results should not be interpreted as evidence that those risk factors are not on the causal path to CAD. Secondly, basing the selection of instrumental variables on an external dataset (e.g. the Global Lipid Genetics Consortium) reduces the risk of winner's course [13].

We performed supplementary analysis with $n = 55$ genetic variants derived from the NMR GWAS as instrumental variables to investigate how much the results depend on the choice of instruments.

## Lipoprotein measures as risk factors

Genetic associations with lipoprotein measures and metabolites are taken from Kettunen et al. [10] who measured 118 variables on 24,925 European individuals using the high-throughput Nightingale NMR platform. The contributing cohorts are mainly Finish (around 50%), with several other Belgium (10%), Dutch (16%), Estonian (14%) and German (10%) cohorts contributing. The majority of samples for measuring the biomarkers were collected after overnight-fasting, otherwise the analyses were adjusted for time to last meal [10]. Estimates were obtained by linear regression of each NMR measurement on each of the genetic variants in turn, with adjustment for age, sex, time from last meal (if non-fasting), and ten genomic principal components. NMR measurements were inverse rank-based normal transformed, so that association estimates are presented in standard deviation units for the relevant risk factor throughout.

Several measurements from the Nightingale platform were highly correlated, judged by the correlation between the genetic associations for the 150 genetic variants. While MR-BMA was able to identify the causal risk factors reliably in a simulation study when risk factors were highly correlated (up to $|r| = 0.99$) [11], several risk factors were more highly correlated than this. We therefore pruned the set of risk factors to avoid inaccurate results due to collinearity. For each lipoprotein diameter category representing the size of lipoproteins, we retained only the measurement of cholesterol and/or triglyceride content, and mean particle diameter where available. We also included only total fatty acid content and not other fatty acid measurements, as genetic predictors that were able to distinguish reliably between these risk factors were not included as instruments. Other non-lipoprotein metabolite measurements were retained in the analysis as they had substantially weaker correlations with lipoprotein measurements, and so would only be selected by MR-BMA if they mediated CAD risk from the genetic predictors included in the model. No pair of risk factors included in the final analysis were more highly correlated than $|r| = 0.99$ (see correlation heatmap in Supplementary Figure A1). Finally, we only included risk factors into the MR analysis that had at least one genetic variant that was a strong predictor (genome-wide significant). The final list of 30 lipoprotein measures and metabolites included in the analysis is provided in Supplementary Table A2.

## Coronary artery disease as outcome

Our primary analysis was based on genetic associations with CAD risk taken from the 2017 CARDIoGRAMplusC4D data release meta-analysed together with UK Biobank [14] including 453,595 individuals mostly of European descent, of whom 113,937 had a CAD event. Genetic association estimates with CAD risk were obtained in each study of the CARDIoGRAMplusC4D consortium by logistic regression with adjustment for at least five genomic principal components, and then meta-analysed across studies. There was one rare genetic variant (rs1998013, effect allele frequency 0.8%, in the *PCSK9* gene region) and one common

intergenic genetic variant (rs894210, effect allele frequency 43.5%) for which there was no association estimate with CAD available. After excluding the missing genetic variants, we performed MR-BMA with 148 variants and 30 risk factors.

As supplementary analyses, we repeated the same analysis steps on the 2017 CARDIoGRAMplusC4D data release except: 1) we omitted the variant in the *APOB* gene region from the analysis, to assess whether this variant was overly influential in determining the top ranked models and 2) we omitted the ApoB measurement from the list of risk factors to see if any other risk factor reached a similar level of evidential support. If it is the case that ApoB was selected as representative for a group of highly correlated traits, then upon removal of ApoB another risk factor of this group should be selected as representative instead.

As sensitivity analyses, we considered 1) an earlier release of CARDIoGRAMplusC4D consortium [15] including 60,801 CAD cases and 123,504 controls of European descent, but not including UK Biobank participants and 2) a UK Biobank GWAS which includes 29,278 cases and 338,425 controls of European descent (defined by self-report and genomic principal components). Quality control procedures were performed and related individuals were excluded from the analysis as described previously [16]. For the main and the two sensitivity analyses we report the results including all variants and after excluding genetic variants that are influential points and outliers.

# Results

## Main analysis using outcome data from CARDIoGRAMplusC4D and UK Biobank

Results are provided in Table 1. We show the top 10 models (i.e. sets of risk factors) ranked according to their model posterior probability, and the top 10 risk factors according to their marginal inclusion probability. We also present the model-averaged causal effect estimate for each risk factor. The top-ranked model contains ApoB and no additional risk factors (model posterior probability 0.464). ApoB is also the risk factor with the strongest overall evidence (marginal inclusion probability 0.868, FDR< 0.005). A diagnostic scatterplot of the genetic associations with the outcome against the genetic associations with ApoB is given in Figure 3. Our primary analysis was performed after model diagnostics, which removed influential and outlying genetic variants from the analysis. Similar results were obtained including all variants in the analysis (Supplementary Table A3).

## Supplementary analysis

As supplementary analyses, we first repeated the primary analysis excluding the genetic variant in the *APOB* gene region, to ensure that this variant was not driving the selection of ApoB as a risk factor. This exclusion did not impact the results (Supplementary Table A4) – ApoB remained the highest ranking individual model (model posterior probability 0.455) and the risk factor with the strongest marginal evidence (marginal inclusion probability 0.862). Secondly, we repeated the primary analysis excluding ApoB from the list of risk factors. No al-

ternative risk factor had similar strength of evidence, suggesting that ApoB is indeed the most important risk factor and not just a representative of a group of highly correlated lipoprotein measures with similar evidence. On exclusion of ApoB, the top risk factors were triglycerides content in small HDL particles (marginal inclusion probability 0.461, FDR< 0.05) and LDL cholesterol (marginal inclusion probability 0.417, FDR< 0.05). Yet, the evidence for these two lipoprotein measures is much weaker compared to the evidence for ApoB in the main analysis.

As final supplementary analysis we used $n = 55$ genetic variants derived from the NMR GWAS as instrumental variables. After removing influential variants and outlying genetic variants, ApoB is the risk factor with the strongest evidence (Supplementary Table A11). This supplementary analysis has less power than the main analysis which is due to a smaller number of genetic variants used as instrumental variables ($n = 55$ based on NMR GWAS while $n = 148$ based on Global Lipids Genetics Consortium), yet it confirms ApoB as the highest ranked risk factor. It is important to consider here the different interpretation which depends on the selection of instruments. For the main analysis instrumental variables were selected based on the Global Lipids Genetics Consortium with the aim to define lipid-related risk factors for CAD. The supplementary analysis in contrast allows for a wider panel of NMR metabolites as risk factors for CAD.

### Sensitivity analysis

As sensitivity analysis, we used genetic associations with CAD risk from two alternative datasets. Results are shown in Table A6. For the earlier release of CARDIoGRAMplusC4D [15], the top ranked model includes ApoB alone (model posterior probability 0.455), and ApoB is the top ranked risk factor overall (marginal inclusion probability 0.673, FDR< 0.005). For UK Biobank, ApoB (marginal inclusion probability 0.325, FDR< 0.05) was ranked second after triglycerides in very small VLDL-cholesterol (marginal inclusion probability 0.456, FDR< 0.01). When looking at the individual models, triglycerides content in very small VLDL-cholesterol particles is ranked first followed by models including both ApoB and a measure of triglycerides content, suggesting an additional causal pathway via triglycerides when deriving genetic associations from UK Biobank analysis.

## Discussion

Our results add to the growing evidence that ApoB is the primary causal determinant for CAD risk amongst lipoprotein measurements [17, 8, 18]. Cholesterol underlies the development of atherosclerosis [19]. It enters the arterial wall within those ApoB-containing lipoprotein particles that are small enough to enter the tunica intima from the circulation; these particles include small VLDL, IDL and LDL particles as well as lipoprotein(a). The recent genetic evidence, together with the results in this work, strongly point towards the direction that the lipid content of the particles in secondary to ApoB [8, 18, 20].

These results do not invalidate LDL-cholesterol as a causal risk factor for CAD risk. Indeed, LDL particles contain an apolipoprotein B molecule, as do IDL and VLDL particles.

ApoB (in particular ApoB-100) represents the total number of hepatic-derived lipoprotein particles [21]. However, this investigation suggests clinical benefit of lowering triglyceride and LDL-C levels is proportional to the absolute change in ApoB. ApoB measurements are independent of particle density, and are not affected by heterogeneity of particle cholesterol content [22]. This is particularly important for accurately capturing the number of small dense LDL particles, which are believed to be associated with atherosclerosis. ApoB has been shown to be a superior measure to LDL-cholesterol in the prediction of CAD risk [23], and in prediction of coronary artery calcification [24]. From a clinical perspective, statins target LDL-cholesterol levels rather than ApoB, suggesting that greater benefit might be obtained from lipid-lowering drugs that target lipoprotein particle number [25]. When analysing data from UK Biobank only, there was also some evidence for triglyceride content measures as an additional risk factor. This was not evident in the main analysis or the sensitivity analysis including data from the earlier CARDIoGRAMplusC4D release. This finding should therefore be interpreted with some caution.

There are some caveats to the interpretation of the results of this study. Although we were able to distinguish between measures of cholesterol content and triglyceride content for some categories of lipoprotein particles, we were not able to distinguish between other lipoprotein measures, such as cholesterol ester and phospholipid content, which correlated almost perfectly with cholesterol content. Previous studies have suggested that the ApoB/ApoA1 ratio may be a relevant risk factor for CAD [26]. However, working on summary-level data we were not able to investigate any other relevant risk factors than those provided by the original data, such as the ratio ApoB/ApoA1 or the ratio of LDL/HDL particles.A further limitation is that there is overlap between individuals in the outcome datasets for the main and sensitivity analyses. For this reason, we refer to them as sensitivity analyses rather than replication analyses, as they assess the robustness of the variable selection algorithm to variations in the outcome dataset, rather than providing an independent replication of the findings.

One key strength of the study is that the genetic associations were derived on mainly fasting samples, which facilitates the interpretation of the results. Fasting measurements represent hepatic derived lipid traits while non-fasting samples also partly reflect gut-derived contributions from chylomicron particles and their remnants. This means that our analysis is well placed to answer causal questions about endogenous lipid pathways, but is less able to answer questions about lipoproteins from dietary sources.

In conclusion, our agnostic investigation to identify risk factors for CAD strongly prioritized ApoB, suggesting that ApoB, representing the number of hepatic-derived lipoprotein particles, is the key determinant of CAD risk amongst lipid-related measurements. This analysis demonstrates the potential of publicly-available genetic association data from high-throughput experiments combined with modern data-adaptive statistical learning techniques for obtaining biological insights into disease aetiology.

# Acknowledgment

This work was supported by the UK Medical Research Council (MC_UU_00002/7). S.B. and V.Z. are supported by Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and

the Royal Society (Grant Number 204623/Z/16/Z).
D.G. was supported by the Wellcome Trust 4i Programme (203928/Z/16/Z) and British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College London.
M.A.K was supported by a research grant from the Sigrid Juselius Foundation, Finland. This work was supported by core funding from: the UK Medical Research Council (MR/L003120/1), the British Heart Foundation (RG/13/13/30194; RG/18/13/33946), the National Institute for Health Research [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust]$^\star$ and Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome.
$^\star$ The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
L.B. was supported by the BHF-Turing Cardiovascular Data Science Awards 2017 and The Alan Turing Institute under the Engineering and Physical Sciences Research Council grant EP/N510129/1.
The research has been conducted using the UK Biobank Resource under Application Number 26865. Lastly, this study would not have been possible without the access to publicly available summary data. We would like to thank the authors of the NMR GWAS (`http://www.computationalmedicine.fi/data`) and the CARDIOGRAMplus4CD (`http://www.cardiogramplusc4d.org/data-downloads/`).

# Conflicts of Interest

A.S.B. has received grants outside of this work from AstraZeneca, Biogen, Bioverativ, Merck, Novartis and Sanofi, and personal fees from Novartis. All other authors declare no competing interests.

# References

[1] Robert Plenge, Edward Scolnick, and David Altshuler. Validating therapeutic targets through human genetics. *Nature Reviews Drug Discovery*, 12(8):581–594, 2013. doi: 10.1038/nrd4051.

[2] P. Linsel-Nitschke, A. Götz, J. Erdmann, I. Braenne, P. Braund, C. Hengstenberg, K. Stark, M. Fischer, S. Schreiber, N.E. El Mokhtari, et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease — a Mendelian randomisation study. *PLoS One*, 3(8):e2986, 2008. doi: 10.1371/journal.pone.0002986.

[3] B.F. Voight, G.M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, M.K. Jensen, G. Hindy, H. Hólm, E.L. Ding, T. Johnson, et al. Plasma HDL cholesterol and

risk of myocardial infarction: a mendelian randomisation study. *The Lancet*, 380(9841): 572–580, 2012. doi: 10.1016/S0140-6736(12)60312-2.

[4] B.M.Y. Cheung, I.J. Lauder, C.P. Lau, and C.R. Kumana. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. *British Journal of Clinical Pharmacology*, 57(5):640–651, 2004. doi: 10.1111/j.1365-2125.2003.02060.x.

[5] Gregory G Schwartz, Anders G Olsson, Markus Abt, Christie M Ballantyne, Philip J Barter, Jochen Brumm, Bernard R Chaitman, Ingar M Holme, David Kallend, Lawrence A Leiter, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. *New England Journal of Medicine*, 367(22):2089–2099, 2012. doi: 10.1056/nejmoa1206797.

[6] A Michael Lincoff, Stephen J Nicholls, Jeffrey S Riesmeyer, Philip J Barter, H Bryan Brewer, Keith AA Fox, C Michael Gibson, Christopher Granger, Venu Menon, Gilles Montalescot, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. *New England Journal of Medicine*, 376(20):1933–1942, 2017.

[7] Ron Do, Cristen J Willer, Ellen M Schmidt, Sebanti Sengupta, Chi Gao, Gina M Peloso, Stefan Gustafsson, Stavroula Kanoni, Andrea Ganna, Jin Chen, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. *Nature Genetics*, 45:1345–1352, 2013. doi: 10.1038/ng.2795.

[8] Brian A. Ference, John J. P. Kastelein, Kausik K. Ray, Henry N. Ginsberg, M. John Chapman, Chris J. Packard, Ulrich Laufs, Clare Oliver-Williams, Angela M. Wood, Adam S. Butterworth, Emanuele Di Angelantonio, John Danesh, Stephen J. Nicholls, Deepak L. Bhatt, Marc S. Sabatine, and Alberico L. Catapano. Association of triglyceride-lowering lpl variants and ldl-c–lowering ldlr variants with risk of coronary heart disease. *JAMA*, 321(4):364–373, 10/3/2019 2019. doi: 10.1001/jama.2018.20045.

[9] Tom G. Richardson, Eleanor Sanderson, Tom M. Palmer, Mika Ala-Korpela, Brian A. Ference, George Davey Smith, and Michael V. Holmes. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable mendelian randomisation analysis. *PLOS Medicine*, 17(3): e1003062–, 03 2020.

[10] Johannes Kettunen, Ayşe Demirkan, Peter Würtz, Harmen HM Draisma, Toomas Haller, Rajesh Rawal, Anika Vaarhorst, Antti J Kangas, Leo-Pekka Lyytikäinen, Matti Pirinen, et al. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of *LPA*. *Nature Communications*, 7:11122, 2016.

[11] Verena Zuber, Johanna Maria Colijn, Caroline Klaver, and Stephen Burgess. Selecting likely causal risk factors from high-throughput experiments using multivariable Mendelian randomization. *Nature Communications*, 11(1):29, 2020. doi: 10.1038/s41467-019-13870-3.

[12] Yoav Benjamini and Yosef Hochberg. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society. Series B (Methodological)*, 57(1):289–300, 1995. ISSN 00359246.

[13] Philip C Haycock, Stephen Burgess, Kaitlin H Wade, Jack Bowden, Caroline Relton, and George Davey Smith. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. *The American Journal of Clinical Nutrition*, 103(4):965–978, 2016. doi: 10.3945/?ajcn.115.118216.

[14] Christopher P Nelson, Anuj Goel, Adam S Butterworth, Stavroula Kanoni, Tom R Webb, Eirini Marouli, Lingyao Zeng, Ioanna Ntalla, Florence Y Lai, Jemma C Hopewell, et al. Association analyses based on false discovery rate implicate new loci for coronary artery disease. *Nature Genetics*, 49(9):1385–1391, 2017. doi: 10.1038/ng.3913.

[15] CARDIoGRAMplusC4D Consortium. A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nature Genetics*, 47:1121–1130, 2015. doi: 10.1038/ng.3396.

[16] Elias Allara, Gabriele Morani, Paul Carter, Apostolos Gkatzionis, Verena Zuber, Christopher N Foley, Jessica M B Rees, Amy M Mason, Steven Bell, Dipender Gill, Sara Lindström, Adam S Butterworth, Emanuele Di Angelantonio, James Peters, Stephen Burgess, and INVENT consortium. Genetic determinants of lipids and cardiovascular disease outcomes: A wide-angled mendelian randomization investigation. *Circulation. Genomic and precision medicine*, 12(12):e002711–e002711, 12 2019. doi: 10.1161/CIRCGEN.119.002711.

[17] PJ Barter, CM Ballantyne, R Carmena, M Castro Cabezas, M John Chapman, P Couture, J De Graaf, PN Durrington, O Faergeman, J Frohlich, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. *Journal of Internal Medicine*, 259(3):247–258, 2006.

[18] Mika Ala-Korpela. The culprit is the carrier, not the loads: cholesterol, triglycerides and apolipoprotein b in atherosclerosis and coronary heart disease. *International Journal of Epidemiology*, 48(5):1389–1392, 1/22/2020 2019. doi: 10.1093/ije/dyz068.

[19] Kevin Huynh, Christopher K. Barlow, Kaushala S. Jayawardana, Jacquelyn M. Weir, Natalie A. Mellett, Michelle Cinel, Dianna J. Magliano, Jonathan E. Shaw, Brian G. Drew, and Peter J. Meikle. High-throughput plasma lipidomics: Detailed mapping of the associations with cardiometabolic risk factors. *Cell Chemical Biology*, 26(1):71–84.e4, 2019. doi: https://doi.org/10.1016/j.chembiol.2018.10.008.

[20] Allan D. Sniderman, George Thanassoulis, Tamara Glavinovic, Ann Marie Navar, Michael Pencina, Alberico Catapano, and Brian A. Ference. Apolipoprotein b particles and cardiovascular disease: A narrative review. *JAMA Cardiology*, 4(12):1287–1295, 1/22/2020 2019. doi: 10.1001/jamacardio.2019.3780.

[21] T Ji Knott, RJ Pease, LM Powell, SC Wallis, SC Rall Jr, TL Innerarity, B Blackhart, WH Taylor, Y Marcel, R Milne, et al. Complete protein sequence and identification of structural domains of human apolipoprotein B. *Nature*, 323(6090):734, 1986.

[22] John H Contois, G Russell Warnick, and Allan D Sniderman. Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. *Journal of clinical lipidology*, 5(4):264–272, 2011.

[23] Carl E Orringer. Non-HDL cholesterol, ApoB and LDL particle concentration in coronary heart disease risk prediction and treatment. *Clinical Lipidology*, 8(1):69–79, 2013.

[24] John T Wilkins, Ron C Li, Allan Sniderman, Cheeling Chan, and Donald M Lloyd-Jones. Discordance between apolipoprotein B and LDL-cholesterol in young adults predicts coronary artery calcification: the CARDIA study. *Journal of the American College of Cardiology*, 67(2):193–201, 2016.

[25] Terry A Jacobson. Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. *Mayo Clinic Proceedings*, 86(8):762–780, 2011.

[26] Samia Mora, James D Otvos, Nader Rifai, Robert S Rosenson, Julie E Buring, and Paul M Ridker. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. *Circulation*, 119(7):931–939, 02 2009. doi: 10.1161/CIRCULATIONAHA.108.816181.

## Tables and Figures




Figure 1: Diagram illustrating multivariable Mendelian randomization for selecting causal risk factors from a large number of candidate risk factors. Legend: $G$ = genetic variants, $X_1, ..., X_d$ = risk factors, $Y$ = outcome, $U$ = confounders, $\theta_j$ = causal effect of risk factor $j$ on the outcome.




Figure 2: Schematic diagram of the study design and results for the main, supplementary, and sensitivity analyses. Selected risk factors are those which had a empirical $p$-value of less than 0.05 after correction for multiple testing.




Figure 3: Estimates of genetic associations with coronary artery disease (CAD) risk ($y$-axis) against genetic associations with apolipoprotein B ($x$-axis) for each genetic variant from the primary analysis using CARDIoGRAMplusC4D and UK Biobank. Outliers removed from the analysis are highlighted as diamonds (◆) and their annotated gene-region is displayed.

| CARDIoGRAMplusC4D and UK Biobank | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | Model | Posterior probability | Causal effect | Risk factor | Marginal inclusion probability | Model-averaged causal effect | Empirical $p-$value | FDR |
| 1 | ApoB | 0.480 | 0.464 | ApoB | 0.868 | 0.392 | 0.0001 | 0.003 |
| 2 | ApoB,S.HDL.TG | 0.043 | 0.349,0.175 | S.HDL.TG | 0.136 | 0.033 | 0.0165 | 0.247 |
| 3 | LDL.C,S.HDL.TG | 0.021 | 0.276,0.301 | LDL.C | 0.075 | 0.015 | 0.0882 | 0.882 |
| 4 | ApoB,M.HDL.C | 0.020 | 0.437,-0.111 | XXL.VLDL.TG | 0.047 | 0.010 | 0.4823 | 0.995 |
| 5 | ApoB,S.LDL.C | 0.014 | 0.570,-0.121 | Serum.C | 0.045 | 0.011 | 0.2295 | 0.995 |
| 6 | ApoB,XXL.VLDL.TG | 0.014 | 0.419,0.112 | IDL.C | 0.042 | 0.008 | 0.2401 | 0.995 |
| 7 | ApoB,XS.VLDL.TG | 0.011 | 0.375,0.099 | S.LDL.C | 0.040 | 0.001 | 0.3745 | 0.995 |
| 8 | ApoB,S.VLDL.C | 0.011 | 0.480,-0.017 | M.HDL.C | 0.038 | -0.005 | 0.2885 | 0.995 |
| 9 | ApoB,LDL.C | 0.011 | 0.522,-0.062 | HDL.C | 0.036 | -0.006 | 0.2266 | 0.995 |
| 10 | ApoB,HDL.C | 0.011 | 0.453,-0.073 | Serum.TG | 0.035 | 0.006 | 0.7583 | 0.995 |

Table 1: Main analysis: Top 10 models (combination of risk factors) ranked by the model posterior probability and top 10 risk factors ranked by the marginal inclusion probability in the primary analysis based on $n$ = 138 genetic variants after model diagnostics. Causal effects are log odds ratios for coronary artery disease per 1 standard deviation increase in the risk factor. Empirical $p$-values are computed using $1,000$ permutations and adjusted for multiple testing using False Discovery Rate (FDR) procedure.

# Supplementary Material

| | First author | Year | Pubmed | $n$ | Cases | Controls | Study names (population) |
|---|---|---|---|---|---|---|---|
| Risk factor | | | | | | | |
| | Kettunen | 2016 | 27005778 | 24,925 | | | NMR GWAS (European, predominantly Finnish) |
| Outcome | | | | | | | |
| Main | Nelson | 2017 | 28714975 | 453,595 | 113,937 | 339,658 | CARDIoGRAMplusC4D (European, South&East Asian) and UK Biobank (European) |
| Sensitivity | Nikpay | 2015 | 26343387 | 184,305 | 60,801 | 123,504 | CARDIoGRAMplusC4D (European, South&East Asian) |
| | UK Biobank (European) | 2019 | 31756303 | 367,703 | 29,278 | 338,425 | UK Biobank (European) |

Supplementary Table A1: Study summary table

| Abbreviation | Lipoprotein and metabolite measurements included |
|---|---|
| XXL.VLDL.TG | Triglyceride content in chylomicrons and extra-extra large VLDL |
| XL.VLDL.TG | Triglyceride content in extra-large VLDL |
| L.VLDL.TG | Triglyceride content in large VLDL |
| M.VLDL.TG | Triglyceride content in medium VLDL |
| S.VLDL.TG | Triglyceride content in small VLDL |
| XS.VLDL.TG | Triglyceride content in extra-small VLDL |
| IDL.TG | Triglyceride content in IDL |
| XL.HDL.TG | Triglyceride content in extra-large HDL |
| S.HDL.TG | Triglyceride content in small HDL |
| Serum.TG | Serum total triglycerides |
| L.VLDL.C | Cholesterol content in large VLDL |
| M.VLDL.C | Cholesterol content in medium VLDL |
| S.VLDL.C | Cholesterol content in small VLDL |
| LDL.C | Cholesterol content in LDL |
| S.LDL.C | Cholesterol content in small LDL |
| IDL.C | Cholesterol content in IDL |
| XL.HDL.C | Cholesterol content in extra-large HDL |
| L.HDL.C | Cholesterol content in large HDL |
| M.HDL.C | Cholesterol content in medium HDL |
| HDL.C | Cholesterol content in HDL |
| Est.C | Esterified cholesterol |
| Serum.C | Serum total cholesterol |
| VLDL.D | VLDL diameter |
| LDL.D | LDL diameter |
| HDL.D | HDL diameter |
| ApoA1 | Apolipoprotein A1 |
| ApoB | Apolipoprotein B |
| SM | Sphingomyelins |
| Tot.FA | Total fatty acids |
| Tot.PG | Total phosphoglycerides |

Supplementary Table A2: List of lipoprotein and metabolite measurements included in the analyses.

| CARDIoGRAMplusC4D and UK Biobank | | | | | | |
|---|---|---|---|---|---|---|
| | Model | Posterior probability | Causal effect | Risk factor | Marginal inclusion probability | Model-averaged causal effect |
| 1 | ApoB | 0.347 | 0.432 | ApoB | 0.706 | 0.298 |
| 2 | ApoB,M.HDL.C | 0.048 | 0.392,-0.17 | M.HDL.C | 0.124 | -0.024 |
| 3 | XS.VLDL.TG | 0.039 | 0.411 | XS.VLDL.TG | 0.103 | 0.032 |
| 4 | ApoB,S.LDL.C | 0.015 | 0.613,-0.208 | IDL.TG | 0.079 | 0.021 |
| 5 | ApoB,SM | 0.014 | 0.501,-0.139 | XXL.VLDL.TG | 0.076 | 0.02 |
| 6 | IDL.TG | 0.014 | 0.38 | IDL.C | 0.074 | 0.018 |
| 7 | ApoB,S.HDL.TG | 0.014 | 0.334,0.151 | LDL.C | 0.052 | 0.005 |
| 8 | ApoB,XS.VLDL.TG | 0.014 | 0.287,0.163 | Serum.TG | 0.049 | 0.014 |
| 9 | ApoB,XXL.VLDL.TG | 0.013 | 0.37,0.156 | Serum.C | 0.048 | 0.009 |

| CARDIoGRAMplusC4D only | | | | | | |
|---|---|---|---|---|---|---|
| | Model | Posterior probability | Causal effect | Risk factor | Marginal inclusion probability | Model-averaged causal effect |
| 1 | ApoB | 0.24 | 0.438 | ApoB | 0.488 | 0.197 |
| 2 | XS.VLDL.TG | 0.058 | 0.42 | IDL.TG | 0.159 | 0.048 |
| 3 | IDL.TG | 0.033 | 0.395 | XS.VLDL.TG | 0.153 | 0.05 |
| 4 | S.VLDL.C | 0.015 | 0.447 | Serum.TG | 0.095 | 0.036 |
| 5 | ApoB,XS.VLDL.TG | 0.014 | 0.272,0.186 | Tot.FA | 0.088 | 0.026 |
| 6 | ApoB,S.HDL.TG | 0.012 | 0.331,0.163 | IDL.C | 0.076 | 0.016 |
| 7 | ApoB,IDL.TG | 0.012 | 0.283,0.167 | S.HDL.TG | 0.07 | 0.016 |
| 8 | IDL.TG,XXL.VLDL. | 0.012 | 0.319,0.256 | XXL.VLDL.TG | 0.067 | 0.016 |
| 9 | ApoB,M.HDL.C | 0.01 | 0.407,-0.127 | Serum.C | 0.065 | 0.016 |
| 10 | ApoB,Serum.TG | 0.01 | 0.318,0.16 | S.LDL.C | 0.064 | 0.011 |

| UK Biobank only | | | | | | |
|---|---|---|---|---|---|---|
| | Model | Posterior probability | Causal effect | Risk factor | Marginal inclusion probability | Model-averaged causal effect |
| 1 | XS.VLDL.TG | 0.205 | 0.459 | XS.VLDL.TG | 0.388 | 0.161 |
| 2 | S.VLDL.C | 0.032 | 0.488 | Tot.FA | 0.321 | 0.139 |
| 3 | HDL.C,Tot.FA | 0.03 | -0.255,0.475 | ApoB | 0.147 | 0.047 |
| 4 | ApoB | 0.023 | 0.452 | IDL.TG | 0.145 | 0.045 |
| 5 | IDL.TG | 0.019 | 0.425 | HDL.C | 0.103 | -0.023 |
| 6 | ApoB,XS.VLDL.TG | 0.014 | 0.191,0.294 | S.VLDL.C | 0.099 | 0.033 |
| 7 | L.HDL.C,Tot.FA | 0.013 | -0.221,0.448 | S.HDL.TG | 0.097 | 0.026 |
| 8 | S.HDL.TG,Tot.FA | 0.011 | 0.329,0.259 | TotPG | 0.089 | -0.032 |
| 9 | Tot.FA,TotPG | 0.01 | 0.883,-0.504 | IDL.C | 0.073 | 0.015 |
| 10 | LDL.C,XS.VLDL.TG | 0.009 | 0.129,0.369 | Serum.TG | 0.072 | 0.026 |

Supplementary Table A3: Analysis including all genetic variants: Top 10 models ranked by the model posterior probability and top 10 risk factors ranked by the marginal inclusion probability including all genetic variants before removing influential genetic variants and outliers. Causal effects are log odds ratios for coronary artery disease per 1 standard deviation increase in the risk factor.

| CARDIoGRAMplusC4D and UK Biobank | | | | | | |
|---|---|---|---|---|---|---|
| | Model | Posterior probability | Causal effect | Risk factor | Marginal inclusion probability | Model-averaged causal effect |
| 1 | ApoB | 0.472 | 0.46 | ApoB | 0.862 | 0.385 |
| 2 | ApoB,S.HDL.TG | 0.043 | 0.343,0.177 | S.HDL.TG | 0.136 | 0.033 |
| 3 | LDL.C,S.HDL.TG | 0.02 | 0.272,0.301 | LDL.C | 0.076 | 0.015 |
| 4 | ApoB,M.HDL.C | 0.019 | 0.435,-0.11 | XXL.VLDL.TG | 0.05 | 0.011 |
| 5 | ApoB,XXL.VLDL.TG | 0.015 | 0.408,0.123 | Serum.C | 0.045 | 0.01 |
| 6 | ApoB,S.LDL.C | 0.015 | 0.571,-0.127 | IDL.C | 0.043 | 0.008 |
| 7 | ApoB,XS.VLDL.TG | 0.012 | 0.367,0.102 | S.LDL.C | 0.041 | 0.001 |
| 8 | ApoB,Serum.TG | 0.011 | 0.385,0.098 | Serum.TG | 0.038 | 0.007 |
| 9 | ApoB,LDL.C | 0.011 | 0.525,-0.071 | M.HDL.C | 0.037 | -0.004 |
| 10 | ApoB,S.VLDL.C | 0.011 | 0.474,-0.015 | HDL.C | 0.035 | -0.005 |

Supplementary Table A4: Supplementary analysis 1: After excluding the genetic variant in the *APOB* gene region, these are the top 10 models judged by posterior probability and top 10 risk factors judged by marginal inclusion probability in the primary analysis based on $n$ = 137 genetic variants. Causal effects are log odds ratios for coronary artery disease per 1 standard deviation increase in the risk factor.

| CARDIoGRAMplusC4D and UK Biobank including all genetic variants ($n$ = 148) | | | | | | |
|---|---|---|---|---|---|---|
| | Model | Posterior probability | Causal effect | Risk factor | Marginal inclusion probability | Model-averaged causal effect |
| 1 | XS.VLDL.TG | 0.127 | 0.411 | XS.VLDL.TG | 0.263 | 0.094 |
| 2 | IDL.TG | 0.046 | 0.38 | IDL.C | 0.213 | 0.059 |
| 3 | S.VLDL.C | 0.041 | 0.44 | IDL.TG | 0.204 | 0.063 |
| 4 | IDL.C,XXL.VLDL.TG | 0.03 | 0.299,0.347 | XXL.VLDL.TG | 0.168 | 0.05 |
| 5 | IDL.TG,XXL.VLDL.TG | 0.022 | 0.304,0.267 | M.HDL.C | 0.162 | -0.037 |
| 6 | M.HDL.C,Serum.C | 0.015 | -0.317,0.367 | Serum.C | 0.116 | 0.034 |
| 7 | LDL.C,XS.VLDL.TG | 0.015 | 0.178,0.286 | LDL.C | 0.114 | 0.026 |
| 8 | IDL.C,S.HDL.TG | 0.012 | 0.241,0.282 | Serum.TG | 0.107 | 0.038 |
| 9 | IDL.C,Serum.TG | 0.011 | 0.219,0.287 | S.VLDL.C | 0.096 | 0.031 |
| 10 | S.LDL.C,XS.VLDL.TG | 0.011 | 0.175,0.294 | S.HDL.TG | 0.079 | 0.019 |

| CARDIoGRAMplusC4D and UK Biobank after model diagnostics ($n$ = 138) | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | Model | Posterior probability | Causal effect | Risk factor | Marginal inclusion probability | Model-averaged causal effect | Empirical $p-$value | FDR |
| 1 | LDL.C,S.HDL.TG | 0.156 | 0.261,0.3 | S.HDL.TG | 0.461 | 0.144 | 0.0021 | 0.025 |
| 2 | IDL.TG | 0.063 | 0.436 | LDL.C | 0.417 | 0.119 | 0.0013 | 0.025 |
| 3 | S.HDL.TG,S.LDL.C | 0.049 | 0.294,0.266 | Serum.C | 0.17 | 0.056 | 0.0143 | 0.087 |
| 4 | IDL.C,S.HDL.TG | 0.048 | 0.237,0.325 | IDL.TG | 0.159 | 0.055 | 0.0151 | 0.087 |
| 5 | L.HDL.C,Serum.C | 0.032 | -0.272,0.381 | S.LDL.C | 0.156 | 0.038 | 0.0274 | 0.101 |
| 6 | HDL.C,Serum.C | 0.027 | -0.277,0.441 | IDL.C | 0.128 | 0.029 | 0.0296 | 0.101 |
| 7 | S.HDL.TG,Serum.C | 0.021 | 0.354,0.23 | L.HDL.C | 0.118 | -0.026 | 0.0181 | 0.087 |
| 8 | LDL.C,XS.VLDL.TG | 0.016 | 0.233,0.249 | HDL.C | 0.095 | -0.019 | 0.0384 | 0.115 |
| 9 | Est.C,S.HDL.TG | 0.014 | 0.197,0.393 | XS.VLDL.TG | 0.076 | 0.017 | 0.0682 | 0.182 |
| 10 | LDL.C,XXL.VLDL.TG | 0.012 | 0.337,0.273 | XXL.VLDL.TG | 0.073 | 0.016 | 0.2636 | 0.575 |

Supplementary Table A5: Supplementary analysis 2: After excluding the ApoB measurement as risk factor from the set of candidate risk factors these are the top 10 models ranked by the posterior probability and top 10 risk factors ranked by the marginal inclusion probability in the primary analysis based on all available genetic variants ($n$ = 148) and after model diagnostics ($n$ = 138). Causal effects are log odds ratios for coronary artery disease per 1 standard deviation increase in the risk factor.

CARDIoGRAMplusC4D only

| | Model | Posterior probability | Causal effect | Risk factor | Marginal inclusion probability | Model-averaged causal effect | Empirical $p-$value | FDR |
|---|---|---|---|---|---|---|---|---|
| 1 | ApoB | 0.394 | 0.455 | ApoB | 0.673 | 0.293 | 0.0001 | 0.003 |
| 2 | ApoB,M.HDL.C | 0.018 | 0.425,-0.121 | LDL.C | 0.107 | 0.027 | 0.0544 | 0.461 |
| 3 | S.VLDL.C | 0.018 | 0.464 | S.LDL.C | 0.097 | 0.027 | 0.0709 | 0.461 |
| 4 | IDL.TG | 0.014 | 0.444 | Serum.TG | 0.084 | 0.028 | 0.0599 | 0.461 |
| 5 | HDL.C,Serum.C | 0.014 | -0.263,0.464 | Serum.C | 0.072 | 0.021 | 0.1176 | 0.510 |
| 6 | LDL.C,Serum.TG | 0.012 | 0.276,0.263 | HDL.C | 0.062 | -0.012 | 0.0974 | 0.506 |
| 7 | ApoB,Serum.TG | 0.011 | 0.369,0.115 | S.VLDL.C | 0.059 | 0.015 | 0.1667 | 0.542 |
| 8 | ApoB,IDL.TG | 0.011 | 0.358,0.109 | IDL.TG | 0.056 | 0.015 | 0.1539 | 0.542 |
| 9 | S.LDL.C | 0.010 | 0.461 | M.HDL.C | 0.055 | -0.008 | 0.1889 | 0.546 |
| 10 | ApoB,S.VLDL.C | 0.010 | 0.402,0.06 | IDL.C | 0.052 | 0.010 | 0.2423 | 0.630 |

UK Biobank only

| | Model | Posterior probability | Causal effect | Risk factor | Marginal inclusion probability | Model-averaged causal effect | Empirical $p-$value | FDR |
|---|---|---|---|---|---|---|---|---|
| 1 | XS.VLDL.TG | 0.195 | 0.435 | XS.VLDL.TG | 0.456 | 0.169 | 0.0002 | 0.006 |
| 2 | ApoB,S.HDL.TG | 0.056 | 0.281,0.233 | ApoB | 0.325 | 0.102 | 0.0010 | 0.015 |
| 3 | ApoB,XS.VLDL.TG | 0.043 | 0.207,0.258 | S.HDL.TG | 0.222 | 0.060 | 0.0061 | 0.061 |
| 4 | ApoB | 0.039 | 0.437 | IDL.TG | 0.109 | 0.027 | 0.0157 | 0.103 |
| 5 | LDL.C,XS.VLDL.TG | 0.024 | 0.14,0.338 | LDL.C | 0.108 | 0.018 | 0.0446 | 0.191 |
| 6 | S.VLDL.C | 0.024 | 0.467 | Serum.TG | 0.104 | 0.032 | 0.0171 | 0.103 |
| 7 | LDL.C,S.HDL.TG | 0.015 | 0.216,0.334 | S.VLDL.C | 0.086 | 0.024 | 0.0444 | 0.191 |
| 8 | S.LDL.C,XS.VLDL.TG | 0.015 | 0.133,0.346 | Tot.FA | 0.079 | 0.018 | 0.0677 | 0.254 |
| 9 | IDL.C,S.HDL.TG | 0.012 | 0.201,0.345 | IDL.C | 0.063 | 0.009 | 0.0994 | 0.331 |
| 10 | ApoB,Serum.TG | 0.012 | 0.273,0.218 | S.LDL.C | 0.059 | 0.003 | 0.1739 | 0.522 |

Supplementary Table A6: Sensitivity analysis: Top 10 models ranked by the posterior probability and top 10 risk factors ranked by the marginal inclusion probability after model diagnostics (including $n$ = 144 genetic variants for CARDIoGRAMplusC4D and $n$ = 141 for UK Biobank). Causal effects are log odds ratios for coronary artery disease per 1 standard deviation increase in the risk factor.

CARDIoGRAMplusC4D and UK Biobank

| | rs | gene region | $Cd1$ | $Cd2$ | $Cd3$ | max $Cd$ |
|---|---|---|---|---|---|---|
| 1 | rs10903129 | TMEM57 | 0.108 | 0.054 | 0.018 | 0.108 |
| 2 | rs2923084 | AMPD3 | 0.049 | 0.069 | 0.068 | 0.069 |
| 3 | rs6489818 | MAPKAPK5 | 0.051 | 0.029 | 0.004 | 0.051 |
| 4 | rs1515110 | NR | 0.013 | 0.042 | 0.027 | 0.042 |
| 5 | rs515135 | APOB | 0.013 | 0.003 | 0.041 | 0.041 |
| 6 | rs6859 | APOE | 0.035 | 0.018 | 0.039 | 0.039 |
| 7 | rs2326077 | intergenic | 0.039 | 0.027 | 0.015 | 0.039 |
| 8 | rs5880 | CETP | 0.001 | 0.038 | 0.023 | 0.038 |
| 9 | rs799160 | intergenic | 0.004 | 0.002 | 0.037 | 0.037 |
| 10 | rs4465830 | ZNF335 | 0.005 | 0.037 | 0.037 | 0.037 |
| | | threshold | 0.457 | 0.696 | 0.457 | |

CARDIoGRAMplusC4D only

| | rs | region | $Cd1$ | $Cd2$ | $Cd3$ | max $Cd$ |
|---|---|---|---|---|---|---|
| 1 | rs261342 | LIPC | 0.008 | 0.024 | 0.911 | **0.911** |
| 2 | rs5880 | CETP | 0.006 | 0.164 | 0.057 | 0.164 |
| 3 | rs515135 | APOB | 0.116 | 0.129 | 0.125 | 0.129 |
| 4 | rs2923084 | AMPD3 | 0.081 | 0.109 | 0.096 | 0.109 |
| 5 | rs10903129 | TMEM57 | 0.078 | 0.012 | 0.025 | 0.078 |
| 6 | rs4530754 | CSNK1G3 | 0.076 | 0.001 | 0.001 | 0.076 |
| 7 | rs6489818 | MAPKAPK5 | 0.062 | 0.005 | 0.009 | 0.062 |
| 8 | rs2326077 | intergenic | 0.039 | 0.016 | 0.015 | 0.039 |
| 9 | rs12133576 | DR1 | 0.036 | 0.006 | 0.004 | 0.036 |
| 10 | rs4465830 | ZNF335 | 0.005 | 0.036 | 0.000 | 0.036 |
| | | threshold | 0.457 | 0.457 | 0.457 | |

UK Biobank only

| | rs | region | $Cd1$ | $Cd2$ | $Cd3$ | $Cd4$ | max $Cd$ |
|---|---|---|---|---|---|---|---|
| 1 | rs10401969 | SUGP1 | 0.302 | 0.224 | 0.248 | 0.096 | 0.302 |
| 2 | rs2923084 | AMPD3 | 0.124 | 0.064 | 0.026 | 0.079 | 0.124 |
| 3 | rs5880 | CETP | 0.107 | 0.033 | 0.025 | 0 | 0.107 |
| 4 | rs2297374 | SLC22A1 | 0.024 | 0.054 | 0.091 | 0.057 | 0.091 |
| 5 | rs10903129 | TMEM57 | 0.012 | 0.051 | 0.005 | 0.071 | 0.071 |
| 6 | rs7703051 | HMGCR | 0.006 | 0.053 | 0.009 | 0.065 | 0.065 |
| 7 | rs6489818 | MAPKAPK5 | 0.005 | 0.032 | 0.001 | 0.055 | 0.055 |
| 8 | rs894210 | intergenic | 0.05 | 0.051 | 0.019 | 0.039 | 0.051 |
| 9 | rs687339 | intergenic | 0.038 | 0.044 | 0.039 | 0.045 | 0.045 |
| 10 | rs998584 | VEGFA | 0.041 | 0.039 | 0.037 | 0.036 | 0.041 |
| | | threshold | 0.457 | 0.457 | 0.696 | 0.457 | |

Supplementary Table A7: Influential genetic variants: This table displays for each study the 10 variants with the largest Cook's distance ($Cd$) and the annotated genomic region based on the best individual models (model posterior probability > 0.02). The maximum $Cd$ of each variant in all models is used for diagnostics. The final row gives the suggested cut-off for Cook's distance and genetic variants with $Cd$ above the threshold are marked in bold.

CARDIoGRAMplusC4D and UK Biobank

| | rs | gene region | $q1$ | $q2$ | $q3$ | max $q$ |
|---|---|---|---|---|---|---|
| 1 | rs1250229 | FN1 | 55.077 | 54.867 | 57.211 | **57.211** |
| 2 | rs6489818 | MAPKAPK5 | 19.308 | 20.150 | 12.288 | **20.150** |
| 3 | rs12801636 | PCNX3 | 15.124 | 14.625 | 15.845 | **15.845** |
| 4 | rs1515110 | NR | 14.697 | 10.106 | 11.196 | **14.697** |
| 5 | rs2290547 | SETD2 | 13.361 | 14.316 | 8.53 | **14.316** |
| 6 | rs2297374 | SLC22A1 | 11.075 | 11.676 | 14.204 | **14.204** |
| 7 | rs10903129 | TMEM57 | 13.910 | 12.503 | 7.369 | **13.910** |
| 8 | rs2925979 | CMIP | 13.787 | 11.646 | 10.338 | **13.787** |
| 9 | rs2240327 | RBM6 | 13.213 | 11.505 | 11.223 | **13.213** |
| 10 | rs4465830 | ZNF335 | 8.194 | 2.964 | 12.962 | **12.962** |
| 11 | rs6450176 | ARL15 | 8.271 | 6.936 | 12.705 | 12.705 |
| 12 | rs731839 | PEPD | 12.596 | 10.504 | 10.14 | 12.596 |
| 13 | rs4148218 | ABCG8 | 11.789 | 12.03 | 12.032 | 12.032 |
| 14 | rs2247056 | HLA | 8.710 | 9.897 | 11.563 | 11.563 |
| 15 | rs9930333 | FTO | 7.213 | 6.599 | 11.191 | 11.191 |
| | | threshold | | | | 12.84801 |

CARDIoGRAMplusC4D only

| | rs | gene region | $q1$ | $q2$ | $q3$ | max $q$ |
|---|---|---|---|---|---|---|
| 1 | rs4530754 | CSNK1G3 | 24.505 | 15.468 | 15.292 | **24.505** |
| 2 | rs6489818 | MAPKAPK5 | 19.513 | 14.598 | 13.255 | **19.513** |
| 3 | rs12801636 | PCNX3 | 16.290 | 16.800 | 16.810 | **16.810** |
| 4 | rs4148218 | ABCG8 | 14.936 | 14.107 | 15.098 | **15.098** |
| 5 | rs1250229 | FN1 | 9.932 | 12.776 | 10.769 | 12.776 |
| 6 | rs952044 | AC090771.2 | 10.333 | 12.468 | 11.714 | 12.468 |
| 7 | rs2297374 | SLC22A1 | 9.125 | 9.187 | 11.492 | 11.492 |
| 8 | rs4465830 | ZNF335 | 7.196 | 5.401 | 11.390 | 11.390 |
| 9 | rs998584 | VEGFA | 8.781 | 11.195 | 7.745 | 11.195 |
| 10 | rs2923084 | AMPD3 | 8.404 | 10.802 | 9.845 | 10.802 |
| | | threshold | | | | 12.84801 |

UK Biobank only

| | rs | gene region | $q1$ | $q2$ | $q3$ | $q4$ | max $q$ |
|---|---|---|---|---|---|---|---|
| 1 | rs2297374 | SLC22A1 | 38.863 | 34.587 | 27.820 | 34.345 | **38.863** |
| 2 | rs1250229 | FN1 | 25.528 | 22.807 | 31.310 | 24.057 | **31.310** |
| 3 | rs6489818 | MAPKAPK5 | 14.222 | 18.563 | 12.616 | 20.625 | **20.625** |
| 4 | rs2240327 | RBM6 | 15.063 | 16.844 | 16.278 | 17.034 | **17.034** |
| 5 | rs687339 | intergenic | 16.284 | 15.452 | 7.003 | 15.328 | **16.284** |
| 6 | rs2925979 | CMIP | 10.424 | 15.160 | 9.803 | 13.903 | **15.160** |
| 7 | rs4148218 | ABCG8 | 14.250 | 14.512 | 11.681 | 14.137 | **14.512** |
| 8 | rs4921914 | NAT2 | 13.259 | 10.640 | 10.262 | 11.642 | **13.259** |
| 9 | rs1186380 | HNF1A-AS1 | 9.758 | 12.067 | 11.982 | 13.168 | **13.168** |
| 10 | rs2241210 | UBE3B | 12.630 | 11.045 | 10.759 | 9.015 | 12.630 |
| | | threshold | | | | | 12.87313 |

Supplementary Table A8: Outlying genetic variants: This table displays for each study the 10 variants with the largest maximum $q$ and the annotated genomic region based on the best individual models (model posterior probability > 0.02). The maximum $q$ of each variant in all models is used for diagnostics. The final row gives the suggested threshold for the $q-$statistic and variants with $q$ above this threshold are given in bold.

$\sigma$ = 0.1

| # | risk factor | *MIP* | $\hat{\theta}_{\text{MACE}}$ |
|---|---|---|---|
| 1 | ApoB | 0.638 | 0.193 |
| 2 | S.HDL.TG | 0.365 | 0.073 |
| 3 | LDL.C | 0.253 | 0.05 |
| 4 | IDL.C | 0.165 | 0.029 |
| 5 | IDL.TG | 0.14 | 0.019 |
| 6 | XXL.VLDL.TG | 0.134 | 0.019 |
| 7 | XS.VLDL.TG | 0.127 | 0.018 |
| 8 | Serum.TG | 0.117 | 0.016 |
| 9 | Serum.C | 0.115 | 0.019 |
| 10 | M.HDL.C | 0.11 | -0.013 |

$\sigma$ = 0.2

| # | risk factor | *MIP* | $\hat{\theta}_{\text{MACE}}$ |
|---|---|---|---|
| 1 | ApoB | 0.759 | 0.307 |
| 2 | S.HDL.TG | 0.261 | 0.061 |
| 3 | LDL.C | 0.144 | 0.031 |
| 4 | XXL.VLDL.TG | 0.099 | 0.018 |
| 5 | IDL.C | 0.091 | 0.018 |
| 6 | Serum.C | 0.076 | 0.016 |
| 7 | M.HDL.C | 0.075 | -0.009 |
| 8 | Serum.TG | 0.071 | 0.011 |
| 9 | S.LDL.C | 0.064 | 0.007 |
| 10 | XS.VLDL.TG | 0.064 | 0.008 |

$\sigma$ = 0.3

| # | risk factor | *MIP* | $\hat{\theta}_{\text{MACE}}$ |
|---|---|---|---|
| 1 | ApoB | 0.818 | 0.355 |
| 2 | S.HDL.TG | 0.201 | 0.048 |
| 3 | LDL.C | 0.105 | 0.022 |
| 4 | XXL.VLDL.TG | 0.072 | 0.014 |
| 5 | IDL.C | 0.064 | 0.012 |
| 6 | Serum.C | 0.061 | 0.014 |
| 7 | M.HDL.C | 0.057 | -0.007 |
| 8 | Serum.TG | 0.051 | 0.008 |
| 9 | HDL.C | 0.048 | -0.007 |
| 10 | S.LDL.C | 0.048 | 0.003 |

$\sigma$ = 0.5

| # | risk factor | *MIP* | $\hat{\theta}_{\text{MACE}}$ |
|---|---|---|---|
| 1 | ApoB | 0.868 | 0.392 |
| 2 | S.HDL.TG | 0.136 | 0.033 |
| 3 | LDL.C | 0.075 | 0.015 |
| 4 | XXL.VLDL.TG | 0.047 | 0.01 |
| 5 | Serum.C | 0.045 | 0.011 |
| 6 | IDL.C | 0.042 | 0.008 |
| 7 | S.LDL.C | 0.04 | 0.001 |
| 8 | M.HDL.C | 0.038 | -0.005 |
| 9 | HDL.C | 0.036 | -0.006 |
| 10 | Serum.TG | 0.035 | 0.006 |

$\sigma$ = 0.7

| # | risk factor | *MIP* | $\hat{\theta}_{\text{MACE}}$ |
|---|---|---|---|
| 1 | ApoB | 0.907 | 0.415 |
| 2 | S.HDL.TG | 0.101 | 0.025 |
| 3 | LDL.C | 0.055 | 0.011 |
| 4 | XXL.VLDL.TG | 0.03 | 0.006 |
| 5 | S.LDL.C | 0.029 | 0 |
| 6 | Serum.C | 0.029 | 0.006 |
| 7 | IDL.C | 0.028 | 0.005 |
| 8 | M.HDL.C | 0.026 | -0.003 |
| 9 | Serum.TG | 0.023 | 0.004 |
| 10 | HDL.C | 0.023 | -0.003 |

Supplementary Table A9: Parameter check for the prior variance $\sigma^2$, ranging from $\sigma$ = 0.1 to $\sigma$ = 0.7. The main analysis used $\sigma$ = 0.5. Abbreviations: *MIP*=marginal inclusion probability, MACE=model-averaged causal effect.

$p$ = 0.01

| # | risk factor | *MIP* | $\hat{\theta}_{\text{MACE}}$ |
|---|---|---|---|
| 1 | ApoB | 0.979 | 0.454 |
| 2 | S.HDL.TG | 0.015 | 0.004 |
| 3 | LDL.C | 0.009 | 0.002 |
| 4 | S.VLDL.C | 0.007 | 0.002 |
| 5 | S.LDL.C | 0.004 | 0 |
| 6 | Serum.C | 0.004 | 0.001 |
| 7 | XS.VLDL.TG | 0.004 | 0.001 |
| 8 | IDL.C | 0.004 | 0.001 |
| 9 | M.HDL.C | 0.004 | 0 |
| 10 | XXL.VLDL.TG | 0.004 | 0.001 |

$p$ = 0.05

| # | risk factor | *MIP* | $\hat{\theta}_{\text{MACE}}$ |
|---|---|---|---|
| 1 | ApoB | 0.929 | 0.426 |
| 2 | S.HDL.TG | 0.071 | 0.017 |
| 3 | LDL.C | 0.039 | 0.008 |
| 4 | Serum.C | 0.022 | 0.005 |
| 5 | S.LDL.C | 0.02 | 0.001 |
| 6 | XXL.VLDL.TG | 0.02 | 0.004 |
| 7 | IDL.C | 0.02 | 0.004 |
| 8 | M.HDL.C | 0.019 | -0.002 |
| 9 | HDL.C | 0.017 | -0.003 |
| 10 | S.VLDL.C | 0.016 | 0.001 |

$p$ = 0.1

| # | risk factor | *MIP* | $\hat{\theta}_{\text{MACE}}$ |
|---|---|---|---|
| 1 | ApoB | 0.868 | 0.392 |
| 2 | S.HDL.TG | 0.136 | 0.033 |
| 3 | LDL.C | 0.075 | 0.015 |
| 4 | XXL.VLDL.TG | 0.047 | 0.01 |
| 5 | Serum.C | 0.045 | 0.011 |
| 6 | IDL.C | 0.042 | 0.008 |
| 7 | S.LDL.C | 0.04 | 0.001 |
| 8 | M.HDL.C | 0.038 | -0.005 |
| 9 | HDL.C | 0.036 | -0.006 |
| 10 | Serum.TG | 0.035 | 0.006 |

$p$ = 0.2

| # | risk factor | *MIP* | $\hat{\theta}_{\text{MACE}}$ |
|---|---|---|---|
| 1 | ApoB | 0.791 | 0.347 |
| 2 | S.HDL.TG | 0.238 | 0.059 |
| 3 | LDL.C | 0.127 | 0.025 |
| 4 | XXL.VLDL.TG | 0.099 | 0.022 |
| 5 | Serum.C | 0.083 | 0.019 |
| 6 | IDL.C | 0.076 | 0.013 |
| 7 | Serum.TG | 0.071 | 0.014 |
| 8 | S.LDL.C | 0.07 | 0.001 |
| 9 | M.HDL.C | 0.068 | -0.008 |
| 10 | HDL.C | 0.068 | -0.01 |

$p$ = 0.3

| # | risk factor | *MIP* | $\hat{\theta}_{\text{MACE}}$ |
|---|---|---|---|
| 1 | ApoB | 0.744 | 0.318 |
| 2 | S.HDL.TG | 0.32 | 0.081 |
| 3 | XXL.VLDL.TG | 0.18 | 0.046 |
| 4 | LDL.C | 0.164 | 0.032 |
| 5 | Serum.TG | 0.117 | 0.025 |
| 6 | Serum.C | 0.11 | 0.023 |
| 7 | IDL.C | 0.106 | 0.018 |
| 8 | S.VLDL.C | 0.103 | -0.014 |
| 9 | M.HDL.C | 0.092 | -0.011 |
| 10 | S.LDL.C | 0.092 | 0.001 |

Supplementary Table A10: Parameter check for the prior probability $p$, ranging from $p$ = 0.01 to $p$ = 0.3. This reflects 0.3 to 9 expected causal risk factors. The main analysis used $p$ = 0.1 reflecting an a priori expected number of 3 causal risk factors. Abbreviations: *MIP*=marginal inclusion probability, MACE=model-averaged causal effect.

| CARDIoGRAMplusC4D and UK Biobank including all NMR GWAS genetic variants ($n$ = 55) | | | | | | |
|---|---|---|---|---|---|---|
| | Model | Posterior probability | Causal effect | Risk factor | Marginal inclusion probability | Model-averaged causal effect |
| 1 | M.VLDL.C,XXL.VLDL.TG | 0.063 | 0.957,-1.018 | M.VLDL.C | 0.325 | 0.312 |
| 2 | IDL.TG | 0.061 | 0.397 | XXL.VLDL.TG | 0.32 | -0.267 |
| 3 | Serum.TG,XXL.VLDL.TG | 0.046 | 0.974,-1.025 | Serum.TG | 0.214 | 0.19 |
| 4 | L.VLDL.C,M.VLDL.C | 0.038 | -1.113,1.224 | XL.VLDL.TG | 0.173 | -0.13 |
| 5 | M.VLDL.C,XL.VLDL.TG | 0.036 | 0.966,-0.961 | IDL.TG | 0.149 | 0.057 |
| 6 | IDL.C | 0.036 | 0.348 | L.VLDL.C | 0.134 | -0.107 |
| 7 | ApoB | 0.023 | 0.369 | L.VLDL.TG | 0.115 | -0.083 |
| 8 | Serum.TG,XL.VLDL.TG | 0.02 | 0.974,-0.954 | IDL.C | 0.1 | 0.033 |
| 9 | L.VLDL.TG,Serum.TG | 0.016 | -0.998,1.065 | S.VLDL.C | 0.095 | 0.044 |
| 10 | S.VLDL.C,XXL.VLDL.TG | 0.013 | 0.565,-0.385 | XS.VLDL.TG | 0.068 | 0.029 |

| CARDIoGRAMplusC4D and UK Biobank after model diagnostics ($n$ = 45) | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | Model | Posterior probability | Causal effect | Risk factor | Marginal inclusion probability | Model-averaged causal effect | Empirical $p-$value | FDR |
| 1 | ApoB | 0.155 | 0.3 | ApoB | 0.492 | 0.153 | 1.0E-04 | 0.004 |
| 2 | S.VLDL.C | 0.077 | 0.269 | S.VLDL.C | 0.246 | 0.068 | 4.0E-04 | 0.009 |
| 3 | ApoB,Crea | 0.047 | 0.318,-0.196 | Crea | 0.241 | -0.049 | 0.026 | 0.247 |
| 4 | Crea,S.VLDL.C | 0.025 | -0.201,0.287 | M.VLDL.C | 0.07 | 0.022 | 0.013 | 0.201 |
| 5 | XS.VLDL.TG | 0.015 | 0.227 | S.LDL.C | 0.069 | 0.014 | 0.030 | 0.247 |
| 6 | ApoB,Gly | 0.014 | 0.303,-0.064 | Phe | 0.067 | -0.011 | 0.137 | 0.441 |
| 7 | ApoB,Phe | 0.011 | 0.306,-0.157 | Gly | 0.067 | -0.004 | 0.043 | 0.276 |
| 8 | S.LDL.C | 0.01 | 0.329 | XS.VLDL.TG | 0.062 | 0.01 | 0.033 | 0.247 |
| 9 | M.VLDL.C | 0.008 | 0.225 | S.HDL.TG | 0.06 | 0.011 | 0.072 | 0.404 |
| 10 | S.HDL.TG | 0.007 | 0.244 | M.HDL.C | 0.06 | -0.01 | 0.117 | 0.441 |

Supplementary Table A11: Supplementary analysis 3: We additionally varied our set of instruments and performed an analysis based on genetic variants associated with any of the measures in the NMR GWAS by Kettunen et al. These are the top 10 models ranked by the posterior probability and top 10 risk factors ranked by the marginal inclusion probability in the primary analysis based on all available genetic variants ($n$ = 55) and after model diagnostics ($n$ = 45). Causal effects are log odds ratios for coronary artery disease per 1 standard deviation increase in the risk factor.




Supplementary Figure A1: Genetic correlation between lipoprotein measures and metabolites based on the $n$ = 148 lipid-associated genetic variants as used in the main analysis. Color-code indicates correlation strength (darkblue=strong positive correlation to darkred=strong negative correlation). The size of the square is proportional to the absolute correlation.




Supplementary Figure A2: Diagnostic plots with Cooks distance: Estimates of genetic associations with the outcome against predicted genetic associations with the outcome from the primary analysis based on $n$ = 138 genetic variants after exclusion of outliers. Here we show the diagnostics for all four top models with posterior probability > 0.02 as given in Main Table 1. Colour code of points indicates influence, as measured by the variant's Cook's distance.




Supplementary Figure A3: Diagnostic plots with Cooks distance: Estimates of genetic associations with the outcome against predicted genetic associations with the outcome from the primary analysis based on $n$ = 138 genetic variants after exclusion of outliers. Here we show the diagnostics for all four top models with posterior probability > 0.02 as given in Main Table 1. Colour code of points indicates heterogeneity, as measured by the variant's $q$-statistic.

# Supplementary Methods

## Mendelian randomization using summarized data

A genetic variant can be used to make causal inferences about the effect of a risk factor on an outcome if it satisfies the three instrumental variable assumptions:

IV1 The variant is associated with the risk factor;

IV2 The variant is not confounded in its associations with the outcome;

IV3 The variant does not influence the outcome directly, only potentially indirectly via its association with the risk factor.

These assumptions imply that a genetic variant behaves analogously to random assignment to a treatment group in a randomized controlled trial, in that it divides the population into subgroups that differ only with respect to their average level of the risk factor [1]. Any difference in the outcome between these groups implies a causal effect of the risk factor on the outcome, analogous to an intention-to-treat effect in a randomized trial [2].

We consider an extension of the Mendelian randomization paradigm known as multivariable Mendelian randomization, in which genetic variants are allowed to influence multiple risk factors, provided that any causal pathway from the genetic variants to the outcome passes via one or more of the measured risk factors [3]. The assumptions for genetic variants to be valid instruments in multivariable Mendelian randomization are:

MV-IV1 Each variant is associated with at least one of the risk factors;

MV-IV2 Variants are not confounded in their associations with the outcome;

MV-IV3 Variants are not associated with the outcome conditional on the risk factors and confounders.

In turn, the assumptions for a risk factor to be included in a multivariable Mendelian randomization model are:

RF1 No risk factor can be linearly explained by any other included risk factor or a combination of multiple risk factors.

RF2 Each risk factor is associated with at least one of the genetic variants.

Assumption RF1 is needed to distinguish between correlated risk factors [4]. RF2 ensures that each risk factor is adequately predicted by the genetic variants selected as instrumental variables in the analysis.

For a particular set of risk factors, causal effects are estimated by weighted linear regression of the genetic associations with the outcome on the genetic associations with the risk factors

$$\beta_Y = \theta_1\beta_{X1} + \theta_2\beta_{X2} + \ldots + \theta_d\beta_{Xd} + \varepsilon, \quad \varepsilon \sim N(0, \mathrm{diag}(\mathrm{se}(\beta_Y)^2)),$$

where $\beta_Y$ is the vector of genetic associations with the outcome of length $n$, with $n$ the number of genetic variants used as instrumental variables, $\mathrm{se}(\beta_Y)$ is the vector of standard errors of these associations of length $n$ and diag the diagonal operator. $\beta_{X1}, \beta_{X2}, \ldots, \beta_{Xd}$ are the genetic associations with the $d$ risk factors, and $\theta_1, \theta_2, \ldots, \theta_d$ are the causal effects of the $d$ risk factors on the outcome. If there are causal relationships between the risk factors, then these parameters represent the direct effects of the risk factors, i.e. the effect of changing the target risk factor keeping all other risk factors constant [4, 5].

## Variable selection and Bayesian model averaging

The model averaging approach is implemented by considering different sets of risk factors in turn [6]. For each risk factor set, MR-BMA fits the relevant multivariable Mendelian randomization model and assigns a score to the set of risk factors considered that captures the posterior probability that this particular model represents the true causal risk factors for the outcome given the observed genetic association data [6]. As prior parameters MR-BMA requires to set an a priori probability for a risk factor to be causal, which is set to 0.1 reflecting an a priori epectation of three causal risk factors. Additionally, the prior variance is set to 0.25. Sensitivity analysis with respect to the prior parameters is important and we can show that ranking is not impacted by the choice of the prior. Results for a wide range of prior specifications are given in Supplementary Table A10 (prior variance) and Supplementary Table A9 (prior probability).

When considering many candidate risk factors, the model space (including all possible combinations of risk factors) may be prohibitively large to consider all possible combinations of risk factors. To alleviate this we have implemented a stochastic search algorithm [7] to explore the relevant model space (all models with a non-negligible posterior probability) in an efficient way.

When the number of risk factors considered is large, the evidence for each particular model may be small. Hence, we average over the models visited and for each risk factor compute its marginal inclusion probability, which is the sum of the posterior probabilities for all models visited that include this particular risk factor. Further, we provide the model-averaged causal effect estimate, representing the average causal effect estimate for the given risk factor across models in which it is included. As is common for variable-selection methods, this is a conservative estimates of the true causal effect and underestimates its magnitude, but may be used for the interpretation of effect direction and for comparison among the risk factors.

## Resampling to compute empirical $p-$values

Empirical $p$-values for the marginal inclusion probability of each risk factor are obtained using a permutation procedure, where the risk factor association data are held constant and the outcome associations of the genetic variants are randomly perturbed [8]. The empirical $p$-value for risk factor $j$ quantifies how extreme the actual observed marginal inclusion probability is with respect to all permuted marginal inclusion probabilities for that particular risk factor. Formally, the empirical $p$-value is computed by the rank ($r_j$) of the actual observed marginal inclusion probability for risk factor $j$ among all permuted marginal inclusion probabilities for risk factor $j$ over the total number of permutations ($n_{perm}$ = 1,000). Following [9] we add one to the computation to obtain the probability that under the null hypothesis the observed marginal inclusion probability has the observed or a higher rank

$$p_j = (r_j + 1)/(n_{perm} + 1).$$

Multiple testing adjustment is done using the Benjamini and Hochberg false discovery rate (FDR) procedure [10].

## Model diagnostics

Two approaches are considered for model diagnostics. Firstly, to identify influential variants for each visited model with a model posterior probability larger than 0.02, we calculated Cook's distance for each genetic variant [11] and excluded all variants that have in any selected model a Cook's distance which exceeds the median of a central $F$-distribution with $d$ and $n-d$ degrees of freedom, where $d$ is the number of risk factors and $n$ the number of genetic variants used as instrumental variables.

Secondly, to identify outlying variants, we consider for each visited model with a model posterior probability larger than 0.02 a version of Cochran's Q statistic used to detect heterogeneity in meta-analysis [12]

$$Q = \sum_{i=1}^{n} q_i = \sum_{i=1}^{n} \mathrm{se}(\beta_{Y_i})^{-2}(\beta_{Y_i} - \hat{\beta}_{Y_i})^2,$$

where $i$ indexes the genetic variants and $\hat{\beta}_{Y_i}$ is the predicted value of the genetic association with the outcome $\beta_{Y_i}$ based on the relevant multivariable Mendelian randomization model. A genetic variant with a high value of $q_i$ (compared to the $0.05/n$th upper tail of a $\chi^2$ distribution with one degree of freedom representing Bonferroni multiple testing adjustment by the number of variants included) in any of the models visited (with a model posterior probability larger than 0.02) was considered to be an outlying variant.

We then repeated the analyses excluding such variants. The reason for excluding outliers and influential variants is that a single genetic variant can have a strong impact on the models visited and subsequently on variable selection. However, in this case for both main and sensitivity analyses, excluding these variants did not change the headline results.

# References


[1] G. Thanassoulis and C.J. O'Donnell. Mendelian randomization: nature's randomized trial in the post-genome era. *Journal of the American Medical Assocation*, 301(22): 2386–2388, 2009. doi: 10.1001/jama.2009.812.

[2] S. Burgess, C. N. Foley, and V. Zuber. Inferring causal relationships between risk factors and outcomes from genome-wide association study data. *Annual Review of Genomics and Human Genetics*, 2018.

[3] S Burgess and Simon G Thompson. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. *American Journal of Epidemiology*, 181(4):251–260, 2015. doi: 10.1093/aje/kwu283.

[4] Eleanor Sanderson, George Davey Smith, Frank Windmeijer, and Jack Bowden. An examination of multivariable Mendelian Randomization in the single-sample and two-sample summary data settings. *International Journal of Epidemiology*, pages dyy262–dyy262, 12 2018.

[5] Stephen Burgess, Deborah J Thompson, Jessica MB Rees, Felix R Day, John R Perry, and Ken K Ong. Dissecting causal pathways using mendelian randomization with summarized genetic data: application to age at menarche and risk of breast cancer. *Genetics*, 2017. doi: 10.1534/genetics.117.300191.

[6] Verena Zuber, Johanna Maria Colijn, Caroline Klaver, and Stephen Burgess. Selecting likely causal risk factors from high-throughput experiments using multivariable Mendelian randomization. *Nature Communications*, 11(1):29, 2020. doi: 10.1038/s41467-019-13870-3.

[7] Chris Hans, Adrian Dobra, and Mike West. Shotgun stochastic search for "large p" regression. *Journal of the American Statistical Association*, 102(478):507–516, 2007. doi: 10.1198/016214507000000121.

[8] Matthew Stephens and David J Balding. Bayesian statistical methods for genetic association studies. *Nat Rev Genet*, 10(10):681–690, Oct 2009. ISSN 1471-0064 (Electronic); 1471-0056 (Linking). doi: 10.1038/nrg2615.

[9] B V North, D Curtis, and P C Sham. A note on the calculation of empirical p values from monte carlo procedures. *American journal of human genetics*, 71(2):439–441, 08 2002. doi: 10.1086/341527.

[10] Yoav Benjamini and Yosef Hochberg. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society. Series B (Methodological)*, 57(1):289–300, 1995. ISSN 00359246.

[11] Laura J Corbin, Rebecca C Richmond, Kaitlin H Wade, Stephen Burgess, Jack Bowden, George Davey Smith, and Nicholas J Timpson. Body mass index as a modifiable risk factor for type 2 diabetes: Refining and understanding causal estimates using Mendelian randomisation. *Diabetes*, 2016. doi: 10.2337/db16-0418.

[12] MDF Greco, Cosetta Minelli, Nuala A Sheehan, and John R Thompson. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. *Statistics in Medicine*, 34(21):2926–2940, 2015. doi: 10.1002/sim.6522.